71 related articles for article (PubMed ID: 36126256)
1. Real-World Experience of Tixagevimab and Cilgavimab (Evusheld) in Rheumatologic Patients on Rituximab.
Ocon AJ; Mustafa SS
J Clin Rheumatol; 2023 Mar; 29(2):109-111. PubMed ID: 36126256
[TBL] [Abstract][Full Text] [Related]
2. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Evusheld safety and efficacy in multiple sclerosis patients.
Liu EN; Real M; Yang JH; Fair A; Whitmire N; Perez A; Wilder C; Rosengren S; Kinkel RP; Graves JS
Mult Scler Relat Disord; 2024 Jun; 88():105733. PubMed ID: 38901372
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases.
Thomas M; Masson M; Bitoun S; Hamroun S; Seror R; Dupuy H; Lazaro E; Richez C; Allanore Y; Avouac J
Rheumatology (Oxford); 2024 May; 63(6):1632-1638. PubMed ID: 37632774
[TBL] [Abstract][Full Text] [Related]
5. Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study.
Nassar MK; Sabry A; Elgamal M; Zeid Z; Abdellateif Abdelghany D; Tharwat S
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138212
[No Abstract] [Full Text] [Related]
6. Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study.
Demel I; Skopal D; Šafránková E; Rozsívalová P; Jindra P; Šrámek J; Turková A; Vydra J; Labská K; Vedrová J; Čerňan M; Szotkowski T; Móciková H; Hynková L; Šušol O; Kováčová I; Belada D; Hájek R
Ann Hematol; 2024 Mar; 103(3):981-992. PubMed ID: 38092996
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis.
Glhoom S; Fergany A; El-Araby D; Abdelkhalek AA; Gomaa A; Zayed EO; Abd-ElGwad M
Eur J Med Res; 2024 Jan; 29(1):27. PubMed ID: 38183123
[TBL] [Abstract][Full Text] [Related]
8. Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience.
Akinosoglou K; Rigopoulos EA; Kaiafa G; Daios S; Karlafti E; Ztriva E; Polychronopoulos G; Gogos C; Savopoulos C
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680160
[TBL] [Abstract][Full Text] [Related]
9. Breakthrough SARS-CoV-2 infections among recipients of tixagevimab-cilgavimab prophylaxis: A citywide real-world effectiveness study.
Lendacki FR; Li L; Forrest GN; Jordan L; Zelinski C; Black SR; Ison MG; Seo JY
Transpl Infect Dis; 2024 Feb; 26(1):e14194. PubMed ID: 37987112
[TBL] [Abstract][Full Text] [Related]
10. Tixagevimab/cilgavimab (AZD7442/Evusheld) prevent from COVID19 in patients with hematologic malignancies under active chemotherapy.
Lee YJ; Kim HK; Kim Y; Park SH; Lim JH; Jung J; Choi YS; Jo JC
Ann Hematol; 2024 Apr; ():. PubMed ID: 38678486
[TBL] [Abstract][Full Text] [Related]
11. Pre-Exposure Prophylaxis and Treatment with Tixagevimab/Cilgavimab for COVID-19 among Immunocompromised Pediatric Patients.
Frączkiewicz J; Pawińska-Wąsikowska K; Szymbor K; Balwierz W; Skoczeń S; Czyżewski K; Kołtan S; Styczyński J; Małecka A; Irga-Jaworska N; Trelińska J; Młynarski W; Zając-Spychała O; Sobkowiak-Sobierajska A; Derwich K; Bal W; Chaber R; Książek A; Szczepański T; Zawitkowska J; Drabko K; Chodała-Grzywacz A; Karolczyk G; Kobierzycki C; Kałwak K
J Clin Med; 2024 Mar; 13(7):. PubMed ID: 38610794
[No Abstract] [Full Text] [Related]
12. Real-World Efficacy of COVID-19 Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab in People with Multiple Sclerosis.
Elias LB; Jaber A; Manzano M; Leekoff M; Sylvester A; Tremblay MA
Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140258
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder.
Stastna D; Vachova M; Dusek P; Fistravec G; Drahota J; Menkyova I; Varju E; Horakova D; Kubala Havrdova E; Nytrova P
Mult Scler Relat Disord; 2024 May; 85():105523. PubMed ID: 38452649
[TBL] [Abstract][Full Text] [Related]
14. Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak.
You J; Tian J; Wu H; Kang W; Wen J; Xu H; Shi W; Wang Z; Wei H; Du Y; Li X; Mu G; Zhou M; Gu Z; Qu J
Expert Rev Anti Infect Ther; 2023; 21(12):1365-1371. PubMed ID: 37855094
[TBL] [Abstract][Full Text] [Related]
15. Tixagevimab-Cilgavimab Decreases the Rate of SARS-CoV-2 Infection Among Solid Organ Transplant Recipients.
Sanayei AM; Montalvan A; Faria I; Ochalla J; Pavlakis M; Blair BM; Alonso CD; Curry M; Saberi B
Transplant Proc; 2023 Oct; 55(8):1784-1792. PubMed ID: 37661468
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions.
Duminuco A; Nardo A; Orofino A; Giunta G; Conticello C; Del Fabro V; Chiarenza A; Parisi MS; Figuera A; Leotta S; Milone G; Cupri A; Cambria D; Di Raimondo F; Romano A; Palumbo GA
Cancer; 2024 Jan; 130(1):41-50. PubMed ID: 37658645
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes after Tixagevimab and Cilgavimab pre-exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk.
Alejo JL; Kim JD; Chiang TPY; Avery RK; Karaba AH; Jefferis A; Warren DS; Massie AB; Tobian AAR; Segev DL; Werbel WA
Clin Transplant; 2023 Apr; 37(4):e14913. PubMed ID: 36651598
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive procedure for injecting Evusheld® for hematological diseases in a single institute.
Imataki O; Yoshida S; Ishida T; Uemura M; Fujita H; Kadowaki N
Ann Hematol; 2024 May; ():. PubMed ID: 38734996
[TBL] [Abstract][Full Text] [Related]
19. Pre-exposure prophylaxis with tixagevimab/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan.
Kawashima I; Hyuga H; Nakadate A; Matsuura M; Sakamoto Y; Suzuki J; Kumagai T; Suzuki M; Koshiishi M; Yamamoto T; Nakajima K; Tanaka M; Kirito K
Int J Hematol; 2023 Dec; 118(6):731-736. PubMed ID: 37747583
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Outcomes After Tixagevimab and Cilgavimab use for Pre-Exposure Prophylaxis Against Coronavirus Disease 2019: A Population-Based Propensity-matched Cohort Study.
Birabaharan M; Hill E; Begur M; Kaelber DC; Martin TCS; Mehta SR
Clin Infect Dis; 2023 Apr; 76(8):1500-1503. PubMed ID: 36380460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
